Treatment of Anti-Factor VIII Antibodies

Philip M. Blatt; Gilbert C. White II; Campbell W. McMillan; Harold R. Roberts

doi:10.1055/s-0038-1651858

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1977; 38(02): 0514-0523
DOI: 10.1055/s-0038-1651858

Original Article

Schattauer GmbH

Treatment of Anti-Factor VIII Antibodies

Authors

Philip M. Blatt

¹Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
Gilbert C. White II

¹Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
Campbell W. McMillan

¹Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.
Harold R. Roberts

¹Departments of Medicine, Pathology, Pediatrics, and Dental Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514, U.S.A.

Abstract

Summary

Bleeding episodes in patients with hemophilia A with anti-factor VIII antibodies are frequently difficult to treat. Factor VIII concentrates administered by continuous infusion or prothrombin complex concentrates (PCC) have been used for treatment. Hemophilia A patients with inhibitors who respond to factor VIII concentrates generally have low to moderate inhibitor titers (generally less than 20 Bethesda units). Those patients who receive PCC are quite difficult to evaluate but promising clinical responses have clearly been observed. This paper describes our experience with both modalities of therapy and will offer specific guidelines for such therapy.

Volltext

Referenzen

References
1 Abildgaard C. F, Bruton M, Harrison J. 1976; Prothrombin complex concentrates (Kon¯yne) in the treatment of hemophilic patients with factor VIII inhibitors. Journal of Pediatrics 88: 200.
2 Allain J. P, Krieger G. R. 1975; Prothrombin complex concentrate in treatment of classical hemophilia with factor VIII antibody. Lancet II: 1203.
3 Blatt P. M, Lundblad R. L, Kingdon H. S, McLean G, Roberts H. R. 1974; Thrombogenic materials in prothrombin complex concentrates. Annals of Internal Medicine 81: 766.
4 Cederbaum A. I, Blatt P. M, Roberts H. R. 1976; Intravascular coagulation with the use of human prothrombin complex concentrates. Annals of Internal Medicine 84: 683.
5 Davey R. J, Shashaty G. G, Rath C. E. 1976; Acute coagulopathy following infusion of prothrombin complex concentrate. American Journal of Medicine 60: 719.
6 Edson J. R. 1974; Prothrombin complex concentrates and thromboses. New England Journal of Medicine 290: 403.
7 Elsinger F. 1975 Shortening of clotting times of hemophilia A plasma with inhibitor induced by activated factor IX concentrates. Vth Congress of the International Society of Thrombosis and Haemostasis, Paris. July 1976.
8 Faria R, Fiumara N. J. 1972; Hepatitis B associated with kon¯yne. New England Journal of Medicine 287: 358.
9 Fekete L. F, Holst S. L, Peetoom F, Deveber L. L. 1972 »Auto« – Factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. Presented at the Fourteenth International Congress of Hematology, Sao Paulo, Brazil . July 1972, abstract #295.
10 Grammens G. L, Breckenridge R. T. 1974; Complications with Christmas factor (factor IX) concentrates. Annals of Internal Medicine 80: 666.
11 Hoofnagle J. H, Aronson D. L, Roberts H. R. 1975; Serologic evidence for hepatitis B virus infection in patients with hemophilia B. Thrombosis et Diathesis Haemorrhagica 33: 606.
12 Kasper C, Kipnis S. 1972; Hepatitis and clotting factor concentrates. Journal of the American Medical Association 221: 510.
13 Kasper C. K. 1973; Post-operative thromboses in hemophilia B. New England Journal of Medicine 289: 160.
14 Kasper C. K. 1975; Thromboembolic complications. Thrombosis et Diathesis Haemorrhagica 33: 640.
15 Kasper C. K, Aledort L. M, Counts R. B, Edson J. R, Fratantoni J, Green D, Hampton J. W, Hilgartner M. W, Lazerson J, Levine P. H, McMillan C. W, Pool J. G, Shapiro S. S, Shulman N. R, Van Eys J. 1975; A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica 34: 869.
16 Kasper C. K, Feinstein D. I. 1976; Rising factor VIII inhibitor titers after Kon¯yne factor IX complex. New England Journal of Medicine 295: 505.
17 King E. G, Clarke M. E, Buchanan D. I. 1972; Acute anemia with factor VIII therapy. Annals of Internal Medicine 77: 323.
18 Kingdon H. S. 1970; Hepatitis after Kon¯yne. Annals of Internal Medicine 73: 656.
19 Kurczynski E. M, Penner J. A. 1974; Activated prothrombin concentrate for patients with factor VIII inhibitors. New England Journal of Medicine 291: 164.
20 Langdell R. D, Wagner R. H, Brinkhous K. M. 1953; Effect of antihemophilic factor on one-stage clotting tests. Journal of Laboratory Clinical Medicine 41: 637.
21 Lusher J. M, Ravindranath Y, Arciniegas E, Green E. 1974; Open heart surgery in a hemophiliac patient. American Journal of Diseases of Children 127: 708.
22 Mannucci P. M, Bader R, Ruggeri Z. M. 1976; Concentrates of clotting – factor IX. Lancet I: 41.
23 Marchesi S. L, Burney R. 1974; Prothrombin complex concentrates and thromboses. New England Journal of Medicine 290: 403.
24 McMillan C. W, Webster W. P, Roberts H. R, Blythe W. B. 1970; Continuous intravenous infusion of factor VIII in classic hemophilia. British Journal of Haematology 18: 659.
25 Orringer E. P, Koury M. J, Blatt P. M, Roberts H. R. 1976; Hemolysis caused by factor VIII concentrates. Archives of Internal Medicine 136: 1018.
26 Penner J. A, Kelly P. E. 1975; Management of patients with factor VIII or IX inhibitors. Seminars in Thrombosis and Hemostasis 1: 386.
27 Kelly P, Penner J. A. 1976; Management with prothrombin complex concentrates. Journal of the American Medical Association 236: 2061.
28 Rosati L. A, Barnes B, Oberman H. A, Penner J. A. 1970; Hemolytic anemia due to anti-A in concentrated antihemophilic factor preparations. Transfusion 10: 139.
29 Roberts H. R, Scales M. B, Madison J. T, Webster W. P, Penick G. D. 1965; A clinical and experimental study of acquired inhibitors to factor VIII. Blood 26: 805.
30 Roberts H. R, Blatt P. M. 1975; Post-transfusion hepatitis following the use of prothrombin complex concentrates. Thrombosis et Diathesis Haemorrhagica 33: 610.
31 Seeler R. A. 1972; Hemolysis due to anti-A and anti-B in factor VIII preparations. Archives of Internal Medicine 130: 101.
32 Steinberg M. H, Dreiling B. J. 1973; Vascular lesions in hemophilia B. New England Journal of Medicine 289: 592.
33 Sultan Y, Brouet J. C, Debre P. 1974; Treatment of inhibitors to factor VIII with activated prothrombin concentrate. New England Journal of Medicine 291: 1087.
34 Triantaphyllopoulos D. C. 1972; Intravascular coagulation following injection of prothrombin complex. American Journal of Clinical Pathology 57: 603.
35 White II G. C, Lundblad R. L, Blatt P. M, Kingdon H. S, Roberts H. R. 1975 Effects of deliberately activated and partially activated prothrombin complex concentrates on normal plasma and on hemophilia A plasma containing an inhibitor of factor VIII. Eighteenth Annual Meeting of the American Society of Hematology, Dallas, Texas..